- Home
- LAES vs ALDX Comparison
LAES vs ALDX Comparison
Compare LAES & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAES
- ALDX
- Stock Information
- Founded
- LAES 2022
- ALDX 2004
- Country
- LAES Switzerland
- ALDX United States
- Employees
- LAES N/A
- ALDX N/A
- Industry
- LAES Semiconductors
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- LAES Technology
- ALDX Health Care
- Exchange
- LAES Nasdaq
- ALDX Nasdaq
- Market Cap
- LAES 315.9M
- ALDX 304.9M
- IPO Year
- LAES N/A
- ALDX 2014
- Fundamental
- Price
- LAES $3.03
- ALDX $6.55
- Analyst Decision
- LAES Strong Buy
- ALDX Strong Buy
- Analyst Count
- LAES 1
- ALDX 2
- Target Price
- LAES $6.00
- ALDX $10.00
- AVG Volume (30 Days)
- LAES 11.6M
- ALDX 729.0K
- Earning Date
- LAES 04-08-2025
- ALDX 05-01-2025
- Dividend Yield
- LAES N/A
- ALDX N/A
- EPS Growth
- LAES N/A
- ALDX N/A
- EPS
- LAES N/A
- ALDX N/A
- Revenue
- LAES $10,981,000.00
- ALDX N/A
- Revenue This Year
- LAES N/A
- ALDX N/A
- Revenue Next Year
- LAES N/A
- ALDX N/A
- P/E Ratio
- LAES N/A
- ALDX N/A
- Revenue Growth
- LAES N/A
- ALDX N/A
- 52 Week Low
- LAES $0.29
- ALDX $2.85
- 52 Week High
- LAES $11.00
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- LAES 48.66
- ALDX 54.11
- Support Level
- LAES $2.79
- ALDX $6.22
- Resistance Level
- LAES $3.22
- ALDX $6.87
- Average True Range (ATR)
- LAES 0.32
- ALDX 0.44
- MACD
- LAES 0.06
- ALDX -0.03
- Stochastic Oscillator
- LAES 45.64
- ALDX 56.30
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.